KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Share-based Compensation: 2018-2025

Historic Share-based Compensation for Aurinia Pharmaceuticals (AUPH) over the last 8 years, with Sep 2025 value amounting to $5.9 million.

  • Aurinia Pharmaceuticals' Share-based Compensation fell 28.92% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.9 million, marking a year-over-year decrease of 50.91%. This contributed to the annual value of $31.6 million for FY2024, which is 30.27% down from last year.
  • Per Aurinia Pharmaceuticals' latest filing, its Share-based Compensation stood at $5.9 million for Q3 2025, which was up 8.81% from $5.4 million recorded in Q2 2025.
  • In the past 5 years, Aurinia Pharmaceuticals' Share-based Compensation ranged from a high of $12.3 million in Q2 2023 and a low of -$3.4 million during Q1 2025.
  • Moreover, its 3-year median value for Share-based Compensation was $8.6 million (2024), whereas its average is $7.7 million.
  • As far as peak fluctuations go, Aurinia Pharmaceuticals' Share-based Compensation spiked by 123.71% in 2021, and later slumped by 159.42% in 2025.
  • Quarterly analysis of 5 years shows Aurinia Pharmaceuticals' Share-based Compensation stood at $8.6 million in 2021, then decreased by 19.53% to $6.9 million in 2022, then skyrocketed by 70.50% to $11.8 million in 2023, then decreased by 23.98% to $8.9 million in 2024, then declined by 28.92% to $5.9 million in 2025.
  • Its Share-based Compensation was $5.9 million in Q3 2025, compared to $5.4 million in Q2 2025 and -$3.4 million in Q1 2025.